PisaczekSearch
文AEN
Diet and nutrition

Insulin and obesity — is this hormone what determines weight gain?

Sources: 12 · Article: 12 726 characters

The Rodzeń brothers link the rise in insulin after carbohydrates to a storage signal and weight gain.

  • Hubert Czerniak explains that an obese person needs a lot of insulin to metabolize fatty tissue.
  • The Rodzeń brothers point out that insulin resistance can affect body weight, among other things.
  • M. Williamson, N. Moustaid-Moussa, and L. Gollahon link prolonged excess insulin to insulin resistance and high blood sugar seen in obesity and diabetes.

What the authors write

Bracia Rodzeń

After eating carbohydrates, insulin levels rise, and the Rodzeń brothers link insulin’s storage signal to weight gain.

„After you eat carbohydrates, the level of insulin in your blood rises significantly. Insulin is a hormone that signals the body to store energy. The more carbohydrates in your food, the faster and more you will gain weight and develop insulin resistance and other metabolic diseases.”Po spożyciu węglowodanów poziom insuliny we krwi znacznie wzrasta. Insulina to hormon, który daje sygnał do magazynowania. Im więcej węglowodanów w Twoich pokarmach, tym szybciej i bardziej przytyjesz, zachorujesz na insulinooporność i inne choroby metaboliczne.
Hubert Czerniak

An obese person needs a lot of insulin to metabolize fatty tissue.

„An obese person needs a great deal of insulin to metabolize fatty tissue. Type III is gestational diabetes. It usually occurs in the second and third trimesters of pregnancy and goes away after delivery. African Americans, Asians, Hispanics, and people who are overweight are particularly at risk, especially those who gained too much weight during pregnancy and those who had this type of diabetes during an earlier pregnancy.”Osoba otyła potrzebuje bowiem bardzo dużo insuliny, aby metabolizować tkankę tłuszczową. Typ III to cukrzyca ciężarnych. Zwykle występuje w drugim i trzecim trymestrze ciąży, a ustępuje wraz z porodem. Szczególnie narażeni są Afroamerykanie, Azjaci, Hiszpanie oraz osoby z nadwagą te, które szczególnie w czasie ciąży przytyły ponad miarę oraz te, które kiedyś miały tę cukrzycę podczas pierwszej ciąży.
Hubert Czerniak

An obese person needs a lot of insulin to metabolize fatty tissue.

„An obese person needs a great deal of insulin to metabolize fatty tissue. Type III is gestational diabetes. It usually occurs in the second and third trimesters of pregnancy and goes away after delivery. African Americans, Asians, Hispanics, and people who are overweight are particularly at risk, especially those who gained too much weight during pregnancy and those who had this type of diabetes during an earlier pregnancy.”Osoba otyła potrzebuje bowiem bardzo dużo insuliny, aby metabolizować tkankę tłuszczową. Typ III to cukrzyca ciężarnych. Zwykle występuje w drugim i trzecim trymestrze ciąży, a ustępuje wraz z porodem. Szczególnie narażeni są Afroamerykanie, Azjaci, Hiszpanie oraz osoby z nadwagą te, które szczególnie w czasie ciąży przytyły ponad miarę oraz te, które kiedyś miały tę cukrzycę podczas pierwszej ciąży.
Bracia Rodzeń

Insulin resistance can affect body weight, among other things.

„Insulin resistance can develop quietly for years. Glucose may still be “normal” while insulin is already working overtime. This mechanism can affect body weight, energy, hormone balance, and metabolic health. Don’t look only at glucose. Understand insulin.”Insulinooporność przez lata może rozwijać się po cichu. Glukoza bywa jeszcze „w normie”, a insulina już pracuje na wysokich obrotach. To mechanizm, który może wpływać na masę ciała, energię, gospodarkę hormonalną i zdrowie metaboliczne. Nie patrz tylko na glukozę. Zrozum insulinę.
M. Williamson i N. Moustaid-Moussa i L. Gollahon

Prolonged excess insulin may contribute to the insulin resistance and high blood sugar seen in obesity and diabetes.

„In contrast, cells exposed to chronic hyperinsulinemia will upregulate IR, IRS1, and PI3K activity, while inhibiting Akt phosphorylation, contributing to chronic insulin resistance and high blood sugar seen in obesity and diabetes (). Further, hyperinsulemia in early stages of diabetes stimulates SGLT2 (Sodium-coupled glucose transporter 2) upregulation in cells of the proximal tubule ().”In contrast, cells exposed to chronic hyperinsulinemia will upregulate IR, IRS1, and PI3K activity, while inhibiting Akt phosphorylation, contributing to chronic insulin resistance and high blood sugar seen in obesity and diabetes (). Further, hyperinsulemia in early stages of diabetes stimulates SGLT2 (Sodium-coupled glucose transporter 2) upregulation in cells of the proximal tubule ().

Research from PubMed · Europe PMC

We selected 5 studies with the best, positive results. This is a selection, not a full review of all research.

Total number of studies on this topic in PubMed: 6 942.

The review indicates that elevated insulin may promote an increase in fatty tissue, while lowering insulin has been associated with lower body weight.

Aim of the study: Lifestyle factors conferring increased diabetes risk are associated with elevated basal insulin levels (hyperinsulinaemia). The latter predicts later obesity in children and adolescents.A causal role of hyperinsulinaemia for adipose tissue growth is probable because pharmacological reduction of insulin secretion lowers body weight in people who are obese.

Results: Genetic inactivation of insulin gene alleles in mice also lowers their systemic insulin levels and prevents or ameliorates high-fat diet-induced obesity. Hyperinsulinaemia causes weight gain because of a physiological property of insulin. Insulin levels that are on the high side of normal, or which are slightly elevated, are sufficient to suppress lipolysis and promote lipogenesis in adipocytes. The effect of insulin on glucose transport or hepatic glucose production requires six or two times higher hormone levels, respectively.It seems justified to suggest a lifestyle that avoids high insulin levels in order to limit anabolic fat tissue activity.

Money for the studynot stated
Do the authors have ties to companies?yes — the authors reported it
Did a manufacturer help with the study?YES
Type of studydiscussion of other studies

“Not stated” does not mean nobody paid — the database does not always record it.

The review describes weight gain as a common effect of insulin therapy, associated, among other things, with changes in blood sugar control and eating.

Aim of the study: Insulin therapy or intensification of insulin therapy commonly results in weight gain in both type 1 and type 2 diabetes. This weight gain can be excessive, adversely affecting cardiovascular risk profile.

Results: Strategies include limiting dose by increasing insulin sensitivity through diet and exercise or by using adjunctive anorectic or insulin-sparing pharmacotherapies such as pramlintide or metformin. Insulin replacement regimens that attempt to mimic physiological norms should also enable insulin to be dosed with maximum efficiency. The novel acylated analogue, insulin detemir, appears to lack the usual propensity for causing weight gain. Elucidation of the pharmacological mechanisms underlying this property might help clarify the mechanisms linking insulin with weight regulation.

Money for the studynot stated
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studydiscussion of other studies

“Not stated” does not mean nobody paid — the database does not always record it.

In a study of people with type 1 diabetes, intensive insulin therapy was associated with greater weight gain than conventional treatment and no diabetes.

Aim of the study: Obesity is a significant health issue for participants with type 1 diabetes undergoing intensive diabetes management. The temporal pattern and factors associated with weight gain after treatment initiation remain poorly understood including how weight gain in participants with and without type I diabetes compare.

Results: Annual weight gain with INT peaked 1.3 years after initiation and was greater than both CONV and controls before and after this peak. Obesity prevalence with INT was lower than controls at baseline, was similar to controls at 2 years and surpassed controls by 5 years. Obesity rates with CONV remained below controls at all time points. Greater annual weight gain in the DCCT was associated with lower haemoglobin A1c , higher insulin dose and family history of type 2 diabetes. Greater weight gain accompanying INT therapy occurs in two stages, leads to similar or greater obesity rates than controls after 2 years and is primarily modified by glucose control and family history, supportive of a therapeutic-genetic influence on weight trajectories.

Money for the studygovernment, public institutions · NHLBI NIH HHS, NIDDK NIH HHS, National Eye Institute
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studystudy with random allocation to groups (RCT)

“Not stated” does not mean nobody paid — the database does not always record it.

The review indicates that excess insulin after administration may contribute to the accumulation of fatty tissue in people with type 1 diabetes.

Aim of the study: Although type 1 diabetes is traditionally considered a disease of lean people, overweight and obesity are becoming increasingly more common in individuals with type 1 diabetes.

Results: Although type 1 diabetes is traditionally considered a disease of lean people, overweight and obesity are becoming increasingly more common in individuals with type 1 diabetes. Non-physiological insulin replacement that causes peripheral hyperinsulinaemia, insulin profiles that do not match basal and mealtime insulin needs, defensive snacking to avoid hypoglycaemia, or a combination of these, are believed to affect body composition and drive excessive accumulation of body fat in people with type 1 diabetes. The consequences of overweight or obesity in people with type 1 diabetes are of particular concern, as they increase the risk of both diabetes-related and obesity-related complications, including cardiovascular disease, stroke, and various types of cancer.

Obesity in people living with type 1 diabetes. · Lancet Diabetes Endocrinol 2021
Money for the studyuniversity or foundation · Fonds Wetenschappelijk Onderzoek
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studydiscussion of other studies

“Not stated” does not mean nobody paid — the database does not always record it.

The review presents research findings in which a low-glycemic-index diet was associated with greater weight loss than a high-glycemic-index diet.

Aim of the study: Although weight loss can be achieved by any means of energy restriction, current dietary guidelines have not prevented weight regain or population-level increases in obesity and overweight. Many high-carbohydrate, low-fat diets may be counterproductive to weight control because they markedly increase postprandial hyperglycemia and hyperinsulinemia.

Results: Long-term studies in animal models have also shown that diets based on high-GI starches promote weight gain, visceral adiposity, and higher concentrations of lipogenic enzymes than do isoenergetic, macronutrientcontrolled, low-GI-starch diets. In a study of healthy pregnant women, a high-GI diet was associated with greater weight at term than was a nutrient-balanced, low-GI diet. In a study of diet and complications of type 1 diabetes, the GI of the overall diet was an independent predictor of waist circumference in men. These findings provide the scientific rationale to justify randomized, controlled, multicenter intervention studies comparing the effects of conventional and low-GI diets on weight control.

Glycemic index and obesity. · Am J Clin Nutr 2002
Money for the studynot stated
Do the authors have ties to companies?not stated
Did a manufacturer help with the study?unknown
Type of studydiscussion of other studies

“Not stated” does not mean nobody paid — the database does not always record it.

Perspectives and opinion materials

The content below presents the authors’ opinions, interpretations and hypotheses. It is not treated as equal to scientific studies and systematic reviews.

Orthomolecular Medicine News Service Opinion material
„A chronically low plasma VC level is a major factor in causing and sustaining weight gain and obesity.”A chronically low plasma VC level is a major factor in causing and sustaining weight gain and obesity.
Orthomolecular Medicine News Service Opinion material
„Contrary to the AHA's long-term advocacy of low-fat diets, studies increasingly show that high-fat ketogenic diets support weight loss, enhance glycemic control, improve lipid profiles and insulin resistance, and reduce inflammation(20–23). Ketogenic diet has been suggested to improve cardiac energetics, reduce oxygen use(24) and even reverse atherogenic dyslipidemia(25). The continued promotion of outdated dietary guidelines reflects a reluctance to adapt to evolving nutritional science, highlighting a critical gap in ASCVD prevention efforts.”Contrary to the AHA's long-term advocacy of low-fat diets, studies increasingly show that high-fat ketogenic diets support weight loss, enhance glycemic control, improve lipid profiles and insulin resistance, and reduce inflammation(20–23). Ketogenic diet has been suggested to improve cardiac energetics, reduce oxygen use(24) and even reverse atherogenic dyslipidemia(25). The continued promotion of outdated dietary guidelines reflects a reluctance to adapt to evolving nutritional science, highlighting a critical gap in ASCVD prevention efforts.
Orthomolecular Medicine News Service Opinion material
„Low-Carb and Ketogenic Nutrition - Metabolic Reversal Without Randomization Type 2 diabetes, obesity, and metabolic syndrome are reversible through carbohydrate restriction and nutritional ketosis-demonstrated in thousands of patients and multiple longitudinal studies [8,56-58]. Yet mainstream medicine hesitated until recently, citing the absence of long-term RCTs. RCTs cannot easily capture dietary adherence, metabolic adaptation, or individualized nutrient balance.”Low-Carb and Ketogenic Nutrition - Metabolic Reversal Without Randomization Type 2 diabetes, obesity, and metabolic syndrome are reversible through carbohydrate restriction and nutritional ketosis-demonstrated in thousands of patients and multiple longitudinal studies [8,56-58]. Yet mainstream medicine hesitated until recently, citing the absence of long-term RCTs. RCTs cannot easily capture dietary adherence, metabolic adaptation, or individualized nutrient balance.

Pisaczek does not judge who is right. It shows what was written and where to read it. Every sentence above has its source.